Cancer
| 5 min read
ReiThera’s gorilla-derived adenovirus vector is helping advance vaccines and therapies for COVID-19, HIV, Ebola, and even cancer.
| 2 min read
The agreement covers clinical supply of bimiralisib, supporting Torqur AG’s phase 2 program in actinic keratosis and broader oncology development.
| 1 min read
ImmuneOncia selects Lonza to manufacture late-stage clinical supply of its PD-L1 antibody Danburstotug for relapsed/refractory NK/T-cell lymphoma.
| 6 min read
Researchers are exploring both broad multi-cancer tests and targeted approaches for hard-to-detect tumors, but clinical validation is still needed.
| 4 min read
Scientists have developed a new CAR-T manufacturing method using a multi-cytokine scaffold that produces longer-lived immune cells capable of self-renewal.
| 3 min read
Bristol Myers Squibb has initiated a phase 1 study of BMS-986506, a cereblon E3 ligase modulator jointly developed with Evotec, triggering a $10 million milestone.
| 2 min read
Chromatin profiling across cancer cell lines maps nuclear enzyme localization, linking metabolic reprogramming to DNA repair and treatment resistance.
| 4 min read
A new bacterial platform can produce millions of stabilized peptides in a single experiment, accelerating the search for therapies against hard-to-drug targets.
| 4 min read
Wake Forest researchers have reprogrammed macrophages to target metastatic tumors in the brain, offering a potential new approach where conventional therapies struggle.
| 4 min read
Emerging clinical trials suggest that the gut microbiome plays a decisive role in how patients respond to immunotherapy.
| 4 min read
Live-cell assays quantify the genetic and metabolic influence on drug selectivity, enabling the development of more precise cancer therapies.
| 5 min read
A new model combines high-resolution experimental data with deep learning to reveal how non-coding DNA sequences control gene activity across different cell types.
